Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2020 December;111(6) > Minerva Medica 2020 December;111(6):551-9

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   Freefree

Minerva Medica 2020 December;111(6):551-9

DOI: 10.23736/S0026-4806.20.06706-3

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Use of clodronate for painful knee prosthesis in osteoarthritis patients: a 6-month pilot study

Gianantonio SAVIOLA 1 , Paolo FERRARI 2, Ernesto NICCOLÒ 2, Andrea CASABELLA 3, Francesco GHELLERE 1, 4, Sonia BONAZZI 1, Abdi-Ali LUL 1, Laura COMINI 5, Luigi MOLFETTA 3

1 Unit of Rheumatology and Rehabilitation, Institute of Castel Goffredo, IRCCS Maugeri Clinical Scientific Institutes, Mantua, Italy; 2 Unit of Orthopedics, San Pellegrino Hospital, Castiglione delle Stiviere, Mantua, Italy; 3 School of Medical and Pharmaceutical Sciences, Research Center of Osteoporosis and Osteoarticular Pathologies, University of Genoa, Genoa, Italy; 4 Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; 5 Scientific Direction of the Institute of Lumezzane, IRCCS Maugeri Clinical Scientific Institutes, Brescia, Italy



BACKGROUND: Knee replacement surgery is one of the most common surgical procedures performed worldwide. Unfortunately, knee prostheses can become painful over time, necessitating appropriate analgesic treatment. Bisphosphonates such as clodronate (CLO) may play an important role in the treatment of painful knee prostheses by virtue of its analgesic and anti-inflammatory properties.
METHODS: In this prospective open label pilot study, eighteen consecutive patients aged 73.2±8.9 years affected by knee painful prosthesis and osteoarthritis were treated with a rehabilitation cycle in addition to i.v. or i.m. CLO. Induction dose was 2.0-2.1g, followed by a weekly dose of 200 mg (i.m.) for 6 months. Visual analogue scale (VAS) pain score and Tegner Lysholm Score (TLS) were used to assess improvement following CLO treatment.
RESULTS: Thirteen out of 18 patients completed the 6-month follow-up. VAS pain score decreased from 8.1±1.8 at baseline to 5.6±2.6 (P<0.05) and TLS increased from 40.4±20.3 at baseline to 62.7±24.1 at 6 months (P<0.05). Univariate regression revealed that among a range of variables, BMI was positively correlated with VAS (r=0.73, P=0.004) and lower TLS after 1 month (r= -0.62, P=0.006).
CONCLUSIONS: CLO in association with rehabilitation exercises can reduce pain and ameliorate the functionality of painful knee prostheses. Administration of a high dose (induction dose) of CLO every 3 months appears to be the most effective regimen compared to a weekly maintenance dose.


KEY WORDS: Pain; Knee prosthesis; Diphosphonates; Rehabilitation

top of page